Sanchez-Rodriguez, Lazaro M.
Bezgin, Gleb http://orcid.org/0000-0002-1069-9201
Carbonell, Felix
Therriault, Joseph
Fernandez-Arias, Jaime
Servaes, Stijn
Rahmouni, Nesrine
Tissot, Cécile
Stevenson, Jenna
Karikari, Thomas K. http://orcid.org/0000-0003-1422-4358
Ashton, Nicholas J.
Benedet, Andréa L.
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Triana-Baltzer, Gallen
Kolb, Hartmuth C.
Rosa-Neto, Pedro http://orcid.org/0000-0001-9116-1376
Iturria-Medina, Yasser http://orcid.org/0000-0002-9345-0347
Funding for this research was provided by:
Canada Research Chairs
Article History
Received: 24 August 2023
Accepted: 19 April 2024
First Online: 4 May 2024
Competing interests
: H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Acumen, ALZPath, BioArctic, Biogen, Eisai, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The other authors declare no competing interests.